[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568597":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":39,"collaborators":10,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":10,"enrollmentInfo":50,"targetDuration":53,"studyType":54,"phases":10,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":62,"whyStopped":10,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Beijing Tiantan Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"3 months DAPT",null,"dual antiplatelet therapy (DAPT) for 3 months",[13],"Drug: DAPT for 3 months after vertebral artery stenting",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","DAPT for 3 months after vertebral artery stenting","After implantation of a drug-eluting stent in the vertebral artery, dual antiplatelet therapy (DAPT) were administered for 3 months. The types of antiplatelet medications are not limited, with the standard regimen consisting of aspirin 100 mg once daily combined with either clopidogrel 75 mg once daily or ticagrelor 90 mg twice daily. Additional antiplatelet agents such as indobufen may also be considered acceptable.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Baixue Jia, MD","CONTACT","+86-15010125093","beckyberry@163.com",[27],{"facility":5,"status":10,"city":28,"state":10,"zip":10,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Beijing","China","CN",{"type":32,"coordinates":33},"Point",[34,35],116.39723,39.9075,{"lat":35,"lon":34},[38],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},{"type":40,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100568597","drug-eluting-stenting-and-short-dual-antiplatelet-therapy-for-preventing-recurrent-stroke-in-vertebral-stenosis-registry-study-100568597",false,"NCT06683300","Drug Eluting Stenting and Short Dual Antiplatelet Therapy for Preventing Recurrent Stroke in Vertebral Stenosis Registry Study","M Short DAPT","Inclusion Criteria:\n\n1. Age ≥18 years old, gender unlimited;\n2. Based on clinical and imaging evidence, the investigators identified patients with symptomatic vertebral atherosclerotic stenosis who met the indications for the placement of drug-eluting vertebral artery stents;\n3. Patients or their guardians sign informed consent.\n\nExclusion Criteria:\n\n1. Severe coagulation dysfunction, serious uncontrolled infection, serious systemic disease, uncontrolled hypertension, etc., are not suitable for surgery;\n2. Patients with aneurysms that cannot be treated in advance or at the same time or are not suitable for surgery;\n3. Myocardial infarction or large-scale cerebral infarction occurred within 2 weeks;\n4. Combined with atrial fibrillation, or accompanied by serious heart, liver, kidney and lung diseases;\n5. Interventional or surgical procedures are planned within 90 days;\n6. Known contraindications to heparin, rapamycin, anesthesia and contrast agents;\n7. Life expectancy is less than 12 months;\n8. The researcher considers it inappropriate to participate in this study.","ALL","18 Years",{"count":51,"type":52},520,"ESTIMATED","1 Year","OBSERVATIONAL","This is a prospective, multi-center, registry study exploring the duration of dual antiplatelet therapy (DAPT) after drug-eluting stent(DES) treatment of symptomatic vertebral artery atherosclerotic stenosis. The trial will be conducted in approximately 30 interventional neurology centers in China.\n\nCurrently, there is no consensus regarding the duration of DAPT after drug-eluting stent treatment for vertebral artery stenosis(VAS). The objective of this study is to standardize clinical medication by shortening the duration of DAPT, thereby reducing the bleeding risk and medication burden for patients, while ensuring that there is no increase in ischemic events.",[57],"Vertebral Artery Stenosis",[59,60,61],"vertebral artery stent","dual antiplatelet duration","symptomatic vertebral artery atherosclerotic stenosis","NOT_YET_RECRUITING","2024-11-08",{"date":65,"type":66},"2024-11-12","ACTUAL",{"date":68,"type":52},"2024-11",{"date":70,"type":52},"2026-12",{"name":5,"class":6},1]